Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy. 2009

Susan A M Mulders, and Walther J A A van den Broek, and Thurman M Wheeler, and Huib J E Croes, and Petra van Kuik-Romeijn, and Sjef J de Kimpe, and Denis Furling, and Gerard J Platenburg, and Geneviève Gourdon, and Charles A Thornton, and Bé Wieringa, and Derick G Wansink
Department of Cell Biology, Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.

Myotonic dystrophy type 1 (DM1) is caused by toxicity of an expanded, noncoding (CUG)n tract in DM protein kinase (DMPK) transcripts. According to current evidence the long (CUG)n segment is involved in entrapment of muscleblind (Mbnl) proteins in ribonuclear aggregates and stabilized expression of CUG binding protein 1 (CUGBP1), causing aberrant premRNA splicing and associated pathogenesis in DM1 patients. Here, we report on the use of antisense oligonucleotides (AONs) in a therapeutic strategy for reversal of RNA-gain-of-function toxicity. Using a previously undescribed mouse DM1 myoblast-myotube cell model and DM1 patient cells as screening tools, we have identified a fully 2'-O-methyl-phosphorothioate-modified (CAG)7 AON that silences mutant DMPK RNA expression and reduces the number of ribonuclear aggregates in a selective and (CUG)n-length-dependent manner. Direct administration of this AON in muscle of DM1 mouse models in vivo caused a significant reduction in the level of toxic (CUG)n RNA and a normalizing effect on aberrant premRNA splicing. Our data demonstrate proof of principle for therapeutic use of simple sequence AONs in DM1 and potentially other unstable microsatellite diseases.

UI MeSH Term Description Entries
D008957 Models, Genetic Theoretical representations that simulate the behavior or activity of genetic processes or phenomena. They include the use of mathematical equations, computers, and other electronic equipment. Genetic Models,Genetic Model,Model, Genetic
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D009223 Myotonic Dystrophy Neuromuscular disorder characterized by PROGRESSIVE MUSCULAR ATROPHY; MYOTONIA, and various multisystem atrophies. Mild INTELLECTUAL DISABILITY may also occur. Abnormal TRINUCLEOTIDE REPEAT EXPANSION in the 3' UNTRANSLATED REGIONS of DMPK PROTEIN gene is associated with Myotonic Dystrophy 1. DNA REPEAT EXPANSION of zinc finger protein-9 gene intron is associated with Myotonic Dystrophy 2. Dystrophia Myotonica,Myotonic Dystrophy, Congenital,Myotonic Myopathy, Proximal,Steinert Disease,Congenital Myotonic Dystrophy,Dystrophia Myotonica 1,Dystrophia Myotonica 2,Myotonia Atrophica,Myotonia Dystrophica,Myotonic Dystrophy 1,Myotonic Dystrophy 2,PROMM (Proximal Myotonic Myopathy),Proximal Myotonic Myopathy,Ricker Syndrome,Steinert Myotonic Dystrophy,Steinert's Disease,Atrophica, Myotonia,Atrophicas, Myotonia,Congenital Myotonic Dystrophies,Disease, Steinert,Disease, Steinert's,Dystrophia Myotonica 2s,Dystrophia Myotonicas,Dystrophica, Myotonia,Dystrophicas, Myotonia,Dystrophies, Congenital Myotonic,Dystrophies, Myotonic,Dystrophy, Congenital Myotonic,Dystrophy, Myotonic,Dystrophy, Steinert Myotonic,Myopathies, Proximal Myotonic,Myopathy, Proximal Myotonic,Myotonia Atrophicas,Myotonia Dystrophicas,Myotonic Dystrophies,Myotonic Dystrophies, Congenital,Myotonic Dystrophy, Steinert,Myotonic Myopathies, Proximal,Myotonica, Dystrophia,Myotonicas, Dystrophia,PROMMs (Proximal Myotonic Myopathy),Proximal Myotonic Myopathies,Steinerts Disease,Syndrome, Ricker
D009841 Oligonucleotides Polymers made up of a few (2-20) nucleotides. In molecular genetics, they refer to a short sequence synthesized to match a region where a mutation is known to occur, and then used as a probe (OLIGONUCLEOTIDE PROBES). (Dorland, 28th ed) Oligonucleotide
D000067879 CELF1 Protein A member of the CELF PROTEINS family which binds GU rich elements (GREs) and CUG-triplet repeats in the 3'UTR of mammalian mRNA transcripts that undergo rapid turnover. It also binds AU-rich elements (AREs or EDEN-like) in the 3'UTR of JUN and FOS mRNAs. Mutations in the human CELF1 gene are associated with MYOTONIC DYSTROPHY type 1. BRUNOL2 Protein,Bruno-Like 2 Protein,CUG Triplet Repeat, RNA-Binding Protein 1,CUGBP, Elav-Like Family Member 1 Protein,CUGBP1 Protein,2 Protein, Bruno-Like,Bruno Like 2 Protein,CUG Triplet Repeat, RNA Binding Protein 1,CUGBP, Elav Like Family Member 1 Protein,Protein, BRUNOL2,Protein, Bruno-Like 2,Protein, CELF1,Protein, CUGBP1
D000483 Alleles Variant forms of the same gene, occupying the same locus on homologous CHROMOSOMES, and governing the variants in production of the same gene product. Allelomorphs,Allele,Allelomorph
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012313 RNA A polynucleotide consisting essentially of chains with a repeating backbone of phosphate and ribose units to which nitrogenous bases are attached. RNA is unique among biological macromolecules in that it can encode genetic information, serve as an abundant structural component of cells, and also possesses catalytic activity. (Rieger et al., Glossary of Genetics: Classical and Molecular, 5th ed) RNA, Non-Polyadenylated,Ribonucleic Acid,Gene Products, RNA,Non-Polyadenylated RNA,Acid, Ribonucleic,Non Polyadenylated RNA,RNA Gene Products,RNA, Non Polyadenylated
D012326 RNA Splicing The ultimate exclusion of nonsense sequences or intervening sequences (introns) before the final RNA transcript is sent to the cytoplasm. RNA, Messenger, Splicing,Splicing, RNA,RNA Splicings,Splicings, RNA
D016376 Oligonucleotides, Antisense Short fragments of DNA or RNA that are used to alter the function of target RNAs or DNAs to which they hybridize. Anti-Sense Oligonucleotide,Antisense Oligonucleotide,Antisense Oligonucleotides,Anti-Sense Oligonucleotides,Anti Sense Oligonucleotide,Anti Sense Oligonucleotides,Oligonucleotide, Anti-Sense,Oligonucleotide, Antisense,Oligonucleotides, Anti-Sense

Related Publications

Susan A M Mulders, and Walther J A A van den Broek, and Thurman M Wheeler, and Huib J E Croes, and Petra van Kuik-Romeijn, and Sjef J de Kimpe, and Denis Furling, and Gerard J Platenburg, and Geneviève Gourdon, and Charles A Thornton, and Bé Wieringa, and Derick G Wansink
March 2011, PLoS genetics,
Susan A M Mulders, and Walther J A A van den Broek, and Thurman M Wheeler, and Huib J E Croes, and Petra van Kuik-Romeijn, and Sjef J de Kimpe, and Denis Furling, and Gerard J Platenburg, and Geneviève Gourdon, and Charles A Thornton, and Bé Wieringa, and Derick G Wansink
July 2019, International journal of molecular sciences,
Susan A M Mulders, and Walther J A A van den Broek, and Thurman M Wheeler, and Huib J E Croes, and Petra van Kuik-Romeijn, and Sjef J de Kimpe, and Denis Furling, and Gerard J Platenburg, and Geneviève Gourdon, and Charles A Thornton, and Bé Wieringa, and Derick G Wansink
November 1996, Nucleic acids research,
Susan A M Mulders, and Walther J A A van den Broek, and Thurman M Wheeler, and Huib J E Croes, and Petra van Kuik-Romeijn, and Sjef J de Kimpe, and Denis Furling, and Gerard J Platenburg, and Geneviève Gourdon, and Charles A Thornton, and Bé Wieringa, and Derick G Wansink
June 2013, Gene,
Susan A M Mulders, and Walther J A A van den Broek, and Thurman M Wheeler, and Huib J E Croes, and Petra van Kuik-Romeijn, and Sjef J de Kimpe, and Denis Furling, and Gerard J Platenburg, and Geneviève Gourdon, and Charles A Thornton, and Bé Wieringa, and Derick G Wansink
February 1999, American journal of human genetics,
Susan A M Mulders, and Walther J A A van den Broek, and Thurman M Wheeler, and Huib J E Croes, and Petra van Kuik-Romeijn, and Sjef J de Kimpe, and Denis Furling, and Gerard J Platenburg, and Geneviève Gourdon, and Charles A Thornton, and Bé Wieringa, and Derick G Wansink
June 1995, Proceedings of the National Academy of Sciences of the United States of America,
Susan A M Mulders, and Walther J A A van den Broek, and Thurman M Wheeler, and Huib J E Croes, and Petra van Kuik-Romeijn, and Sjef J de Kimpe, and Denis Furling, and Gerard J Platenburg, and Geneviève Gourdon, and Charles A Thornton, and Bé Wieringa, and Derick G Wansink
December 2018, Drug discovery today,
Susan A M Mulders, and Walther J A A van den Broek, and Thurman M Wheeler, and Huib J E Croes, and Petra van Kuik-Romeijn, and Sjef J de Kimpe, and Denis Furling, and Gerard J Platenburg, and Geneviève Gourdon, and Charles A Thornton, and Bé Wieringa, and Derick G Wansink
November 1993, Genomics,
Susan A M Mulders, and Walther J A A van den Broek, and Thurman M Wheeler, and Huib J E Croes, and Petra van Kuik-Romeijn, and Sjef J de Kimpe, and Denis Furling, and Gerard J Platenburg, and Geneviève Gourdon, and Charles A Thornton, and Bé Wieringa, and Derick G Wansink
October 2007, Current opinion in neurology,
Susan A M Mulders, and Walther J A A van den Broek, and Thurman M Wheeler, and Huib J E Croes, and Petra van Kuik-Romeijn, and Sjef J de Kimpe, and Denis Furling, and Gerard J Platenburg, and Geneviève Gourdon, and Charles A Thornton, and Bé Wieringa, and Derick G Wansink
March 1992, Science (New York, N.Y.),
Copied contents to your clipboard!